Trial Profile

Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedolizumab (Primary)
Indications Crohn's disease; Ulcerative colitis
Focus Adverse reactions
Sponsors Takeda

Most Recent Events

09 Mar 2023 Status changed from active, no longer recruiting to completed.
26 Oct 2022 According to Results presented at American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022, Vedolizumab Pregnancy Exposure Registry is ongoing with formal statistical analysis planned once the study is completed in 2023.
26 Oct 2022 Results of preliminary descriptive outcomes presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com